Results 51 to 60 of about 337 (198)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

An Earth-sized Planet on the Verge of Tidal Disruption

The Astronomical Journal
TOI-6255 b (GJ 4256) is an Earth-sized planet (1.079 ± 0.065 R _⊕ ) with an orbital period of only 5.7 hr. With the newly commissioned Keck Planet Finder and CARMENES spectrographs, we determine the planet’s mass to be 1.44 ± 0.14 M _⊕ .
Fei Dai, Andrew W. Howard, Samuel Halverson, Jaume Orell-Miquel, Enric Pallé, Howard Isaacson, Benjamin Fulton, Ellen M. Price, Mykhaylo Plotnykov, Leslie A. Rogers, Diana Valencia, Kimberly Paragas, Michael Greklek-McKeon, Jonathan Gomez Barrientos, Heather A. Knutson, Erik A. Petigura, Lauren M. Weiss, Rena Lee, Casey L. Brinkman, Daniel Huber, Gumundur Stefánsson, Kento Masuda, Steven Giacalone, Cicero X. Lu, Edwin S. Kite, Renyu Hu, Eric Gaidos, Michael Zhang, Ryan A. Rubenzahl, Joshua N. Winn, Te Han, Corey Beard, Rae Holcomb, Aaron Householder, Gregory J. Gilbert, Jack Lubin, J. M. Joel Ong, Alex S. Polanski, Nicholas Saunders, Judah Van Zandt, Samuel W. Yee, Jingwen Zhang, Jon Zink, Bradford Holden, Ashley Baker, Max Brodheim, Ian J. M. Crossfield, William Deich, Jerry Edelstein, Steven R. Gibson, Grant M. Hill, Sharon R Jelinsky, Marc Kassis, Russ R. Laher, Kyle Lanclos, Scott Lilley, Joel N. Payne, Kodi Rider, Paul Robertson, Arpita Roy, Christian Schwab, Abby P. Shaum, Martin M. Sirk, Chris Smith, Adam Vandenberg, Josh Walawender, Sharon X. Wang, Shin-Ywan (Cindy) Wang, Edward Wishnow, Jason T. Wright, Sherry Yeh, José A. Caballero, Juan C. Morales, Felipe Murgas, Evangelos Nagel, Ansgar Reiners, Andreas Schweitzer, Hugo M. Tabernero, Mathias Zechmeister, Alton Spencer, David R. Ciardi, Catherine A. Clark, Michael B. Lund, Douglas A. Caldwell, Karen A. Collins, Richard P. Schwarz, Khalid Barkaoui, Cristilyn Watkins, Avi Shporer, Norio Narita, Akihiko Fukui, Gregor Srdoc, David W. Latham, Jon M. Jenkins, George R. Ricker, Sara Seager, Roland Vanderspek   +96 more
doaj   +1 more source

Folate reference interval estimation in the Dutch general population

Practical Laboratory Medicine, 2019
Background: Folate functions as an enzyme co-factor within the one-carbon metabolic pathway, providing key metabolites required for DNA synthesis and methylation. Hence, insufficient intake of folate can negatively affect health.
Michel J. Vos, L. Joost van Pelt, Maarten B. Kok, D.A. Janneke Dijck-Brouwer, M. Rebecca Heiner-Fokkema, Lambert D. Dikkeschei, Jenny E. Kootstra-Ros   +6 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source